Company Overview
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +5.29% |
| 6 Months: | +34.47% |
| 3 Months: | +47.63% |
| 1 Month: | +31.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross4d ago
- RSI (14)55.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BHVN Biohaven Ltd. R2K | 14.94 | -2.68 | $2.25B | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -55.49M | -89.77M | -197.11M | -67.64M | -77.78M | -94.01M | -110.55M | -183.24M | -333.77M | -178.17M | -221.56M | -211.70M | -169.38M | -130.43M |
| Net Income | -62.12M | -45.42M | -54.37M | -97.03M | -203.29M | -68.85M | -70.49M | -90.35M | -102.57M | -179.50M | -319.77M | -160.30M | -221.68M | -198.15M | -173.44M | -130.53M |
| Diluted EPS | - | - | -1.38 | -2.46 | -5.16 | -1.75 | -1.03 | -1.32 | -1.50 | -2.20 | -3.64 | -1.70 | -2.17 | -1.94 | -1.64 | -0.88 |
| R&D Expense | - | - | 46.97M | 70.10M | 177.09M | 52.84M | 63.46M | 79.49M | 95.52M | 155.97M | 314.82M | 157.61M | 187.58M | 184.37M | 141.17M | 103.83M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -114.51M | -218.90M | -567.93M | -436.05M | -885.11M | -745.38M |
| Net Income | -118.67M | -213.80M | -570.28M | -408.17M | -846.42M | -738.82M |
| Diluted EPS | -3.01 | -5.43 | -12.75 | -5.73 | -9.28 | -6.86 |
| R&D Expense | 98.46M | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 661.78M | 513.21M | 615.11M | 451.45M |
| Current Assets | - | - | - | 586.97M | 442.45M | 538.47M | 368.33M |
| Cash & Equivalents | - | 82.51M | - | 204.88M | 248.40M | 99.13M | 229.96M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | 9.91M | 46.14M | 13.25M | 2.60M | - |
| Total Liabilities | - | - | - | 123.01M | 85.24M | 191.67M | 399.38M |
| Current Liabilities | - | - | - | 90.02M | 55.42M | 154.23M | 115.93M |
| Long Term Debt | - | - | - | - | - | - | 238.90M |
| Total Debt | - | - | - | 33.60M | 30.88M | 36.58M | 284.61M |
| Total Equity | 14.45M | 16.78M | - | 538.77M | 427.98M | 423.44M | 52.07M |
| Shares Outstanding | - | - | - | 68.19M | 81.12M | 101.22M | 132.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -75.96M | -145.84M | -297.69M | -331.73M | -582.45M | -609.44M |
| Investing Cash Flow | -2.70M | 944.00K | -304.79M | 129.83M | -244.97M | 300.56M |
| Financing Cash Flow | 152.24M | 138.45M | 767.60M | 211.91M | 677.77M | 439.12M |
| Capital Expenditure | -1.10M | -938.00K | -6.07M | -3.05M | -4.05M | -715.00K |
| Free Cash Flow | -77.05M | -146.78M | -303.76M | -334.77M | -586.50M | -610.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -707.2% | - | -105.8% | -95.4% | -199.9% | -1,418.8% |
| ROCE % | - | - | -99.3% | -95.3% | -192.0% | -222.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 11.65% | 17.53M | $282.66M |
| 2 | Blackrock Inc. | 7.45% | 11.22M | $180.91M |
| 3 | Suvretta Capital Management, LLC | 6.83% | 10.29M | $165.83M |
| 4 | Stifel Financial Corporation | 6.60% | 9.94M | $160.25M |
| 5 | State Street Corporation | 4.40% | 6.62M | $106.70M |
| 6 | Infinitum Asset Management, LLC | 4.15% | 6.25M | $100.75M |
| 7 | TCG Crossover Management, LLC | 3.08% | 4.63M | $74.66M |
| 8 | Royalty Pharma Sub-manager, LLC | 1.95% | 2.94M | $47.34M |
| 9 | Shaw D.E. & Co., Inc. | 1.89% | 2.85M | $45.90M |
| 10 | Geode Capital Management, LLC | 1.84% | 2.77M | $44.62M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHVN
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
- Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development - Combined leadership team p…
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?
Biohaven announced a series of scientific leadership changes, including the upcoming transition of Bruce Car, Ph.D., to Chief Innovation Officer, the promotion of David Pirman, Ph.D., to Executive Vice President and Head of Discovery, and t…
Biohaven Announces Scientific Leadership Transitions
Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice Pre…
Biohaven (BHVN) Completes Enrollment in RISE3 Trial
Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Performing American Stocks in June 2026. On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-cont…
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts
The company is expected to announce clinical data for hard-to-treat epilepsy and obesity later this year.
BHVN — Frequently Asked Questions
What is the current share price of Biohaven Ltd. (BHVN)?
As of 2026-07-14 21:23 PDT, Biohaven Ltd. (BHVN) trades at $14.94 on NYSE. Its 52-week range is $7.79 to $18.11.
What is the market capitalisation of BHVN?
Biohaven Ltd. (BHVN) has a market capitalisation of $2.25B on NYSE.
What is the P/E ratio of BHVN?
BHVN trades at a trailing price-to-earnings (P/E) ratio of -2.68. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 13.12.
Is BHVN a good stock to buy?
This page provides a data-driven analysis of Biohaven Ltd. (BHVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.